{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:48:54Z","timestamp":1791938934014,"version":"4.3.4"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82200161"],"award-info":[{"award-number":["82200161"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Leukemia Precision Diagnosis and Treatment Innovation Platform","award":["2024ZY01053"],"award-info":[{"award-number":["2024ZY01053"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Res."],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s44313-026-00180-z","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:52:59Z","timestamp":1791921179000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Venetoclax combined with\u00a0olverembatinib and prednisone as a frontline therapeutic strategy for Philadelphia chromosome-positive mixed-phenotype acute leukemia"],"prefix":"10.1007","volume":"61","author":[{"given":"Xia","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yile","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangjie","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyan","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huafeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,13]]},"reference":[{"issue":"7","key":"180_CR1","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1038\/s41375-018-0058-4","volume":"32","author":"M Maruffi","year":"2018","unstructured":"Maruffi M, et al. Therapy for children and adults with mixed phenotype acute leukemia: a systematic review and meta-analysis. Leukemia. 2018;32(7):1515\u201328.","journal-title":"Leukemia"},{"issue":"2","key":"180_CR2","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/MOH.0000000000000570","volume":"27","author":"O Wolach","year":"2020","unstructured":"Wolach O, Stone RM. Optimal therapeutic strategies for mixed phenotype acute leukemia. Curr Opin Hematol. 2020;27(2):95\u2013102.","journal-title":"Curr Opin Hematol"},{"issue":"11","key":"180_CR3","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1182\/blood-2010-10-314682","volume":"117","author":"E Matutes","year":"2008","unstructured":"Matutes E, et al. Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification. Blood. 2008;117(11):3163\u201371.","journal-title":"Blood"},{"key":"180_CR4","doi-asserted-by":"publisher","first-page":"e2500494","DOI":"10.1200\/PO-25-00494","volume":"9","author":"H Goulart","year":"2025","unstructured":"Goulart H, et al. Clinical outcomes of adult patients with newly diagnosed mixed phenotype acute leukemia. JCO Precis Oncol. 2025;9:e2500494.","journal-title":"JCO Precis Oncol"},{"issue":"9","key":"180_CR5","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1002\/ajh.25873","volume":"95","author":"A Qasrawi","year":"2020","unstructured":"Qasrawi A, et al. Prognostic impact of Philadelphia chromosome in mixed phenotype acute leukemia (MPAL): a cancer registry analysis on real-world outcome. Am J Hematol. 2020;95(9):1015\u201321.","journal-title":"Am J Hematol"},{"issue":"4","key":"180_CR6","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/ejh.12343","volume":"93","author":"H Shimizu","year":"2014","unstructured":"Shimizu H, et al. Philadelphia chromosome\u2010positive mixed phenotype acute leukemia in the imatinib era. Eur J Haematol. 2014;93(4):297\u2013301.","journal-title":"Eur J Haematol"},{"issue":"6","key":"180_CR7","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1038\/s41375-018-0315-6","volume":"33","author":"M Scherr","year":"2019","unstructured":"Scherr M, et al. Optimized induction of mitochondrial apoptosis for chemotherapy-free treatment of BCR-ABL+acute lymphoblastic leukemia. Leukemia. 2019;33(6):1313\u201323.","journal-title":"Leukemia"},{"key":"180_CR8","doi-asserted-by":"crossref","unstructured":"Wang H, et al. Venetoclax-ponatinib for T315I\/compound-mutated Ph+ acute lymphoblastic leukemia. Blood Cancer J. 2022;12(1):20.","DOI":"10.1038\/s41408-022-00621-9"},{"issue":"1","key":"180_CR9","doi-asserted-by":"publisher","first-page":"2237790","DOI":"10.1080\/16078454.2023.2237790","volume":"28","author":"JY Zou","year":"2023","unstructured":"Zou JY, et al. Combination of venetoclax with BCR-ABL tyrosine kinase inhibitor as a therapeutic strategy for Philadelphia chromosome-positive leukemias. Hematology. 2023;28(1):2237790.","journal-title":"Hematology"},{"issue":"7","key":"180_CR10","first-page":"2519","volume":"111","author":"Y Zhang","year":"2026","unstructured":"Zhang Y, et al. A lower-intensity, venetoclax-containing protocol is effective in adults with newly diagnosed mixed-phenotype acute leukemia. Haematologica. 2026;111(7):2519\u201323.","journal-title":"Haematologica"},{"issue":"6","key":"180_CR11","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1002\/ajh.27289","volume":"99","author":"H Tang","year":"2024","unstructured":"Tang H, et al. A new chemotherapy-free regimen of olverembatinib in combination with venetoclax and dexamethasone for newly diagnosed Ph+ acute lymphoblastic leukemia: Preliminary outcomes of a prospective study. Am J Hematol. 2024;99(6):1177\u20139.","journal-title":"Am J Hematol"},{"issue":"12","key":"180_CR12","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H Dohner","year":"2022","unstructured":"Dohner H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345\u201377.","journal-title":"Blood"},{"key":"180_CR13","doi-asserted-by":"publisher","first-page":"107665","DOI":"10.1016\/j.leukres.2025.107665","volume":"151","author":"S Shi","year":"2025","unstructured":"Shi S, et al. Molecular genetic characterization of mixed-phenotype acute leukemia (MPAL) with BCR::ABL1 fusion. Leuk Res. 2025;151:107665.","journal-title":"Leuk Res"},{"issue":"4","key":"180_CR14","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1002\/ajh.27246","volume":"99","author":"KW Pratz","year":"2024","unstructured":"Pratz KW, et al. Long-term follow-up of VIALE-A: venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia. Am J Hematol. 2024;99(4):615\u201324.","journal-title":"Am J Hematol"},{"issue":"6","key":"180_CR15","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.bbmt.2016.02.013","volume":"22","author":"R Munker","year":"2016","unstructured":"Munker R, et al. Allogeneic hematopoietic cell transplantation for patients with mixed phenotype acute leukemia. Biol Blood Marrow Transplant. 2016;22(6):1024\u20139.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"180_CR16","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.3324\/haematol.2017.174441","volume":"102","author":"R Munker","year":"2017","unstructured":"Munker R, et al. Mixed phenotype acute leukemia: outcomes with allogeneic stem cell transplantation. A retrospective study from the Acute Leukemia Working Party of the EBMT. Haematologica. 2017;102(12):2134\u201340.","journal-title":"Haematologica"}],"container-title":["Blood Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-026-00180-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s44313-026-00180-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-026-00180-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:03:37Z","timestamp":1791936217000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s44313-026-00180-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,13]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["180"],"URL":"https:\/\/doi.org\/10.1007\/s44313-026-00180-z","relation":{},"ISSN":["2287-979X","2288-0011"],"issn-type":[{"value":"2287-979X","type":"print"},{"value":"2288-0011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,13]]},"assertion":[{"value":"15 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"65"}}